4 completed, 3 active not recruiting, 2 recruiting, 2 terminated. 7 Phase 2, 2 Not applicable, 2 Phase 1, 2 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 7 | Completed 3, Active not recruiting 2, Recruiting 1, Terminated 1 |
| Not applicable | 2 | Recruiting 1, Unknown 1 |
| Phase 1 | 2 | Completed 2 |
| Phase 3 | 2 | Active not recruiting 1, Terminated 1 |
Follow Chronic Lymphoid Leukemia: new trials by email Literature Review of Chronic Lymphoid Leukemia trials Research Report on Chronic Lymphoid Leukemia
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Reassessment of the Risk of Hemolytic Syndrome in Patients With Chronic Lymphocytic Leukemia Treated With a Regimen Containing Venetoclax Cervical, Thoracic, Abdominal, and Pelvic CT Scan - Chronic Lymphoid Leukemia | Not applicable | Recruiting | Private Hospital of Confluent, France | 130 | 2026-09-30 | 2026-10-13 |
| Evaluation of the Ambulatory Medical Assistance Nurse Program in Chronic Lymphocytic Leukemia Ambulatory medical assistance - Chronic Lymphoid Leukemia | Not applicable | Unknown | University Hospital, Toulouse | 450 | 2023-04-13 | 2023-09-21 |
| Efficacy of Acalabrutinib in Very Old or Frail Patients With Treatment-naïve or Relapsed/Refractory CLL Acalabrutinib - Chronic Lymphoid Leukemia | Phase 2 | Completed | German CLL Study Group | 53 | 2021-06-01 | 2025-06-08 |
| Ibrutinib Monotherapy Versus Fixed-duration Venetoclax Plus Obinutuzumab Versus Fixed-duration Ibrutinib Plus Venetoclax in Patients With Previously Untreated Chronic Lymphocytic Leukaemia (CLL) Ibrutinib, Venetoclax, Obinutuzumab - Chronic Lymphoid Leukemia | Phase 3 | Active not recruiting | German CLL Study Group | 897 | 2021-03-01 | 2026-04-30 |
| Sequential Regimen of Bendamustine Followed by Obinutuzumab (GA101), Zanubrutinib (BGB-3111) and Venetoclax (ABT-199) in Patients With Relapsed/Refractory CLL Bendamustine, Obinutuzumab, Zanubrutinib - Chronic Lymphoid Leukemia | Phase 2 | Active not recruiting | German CLL Study Group | 42 | 2020-10-01 | 2026-08-20 |
| The Incidence of Hepatitis B in Diffuse Large B-Cell Lymphoma/Chronic Lymphoid Leukemia HBsAg-positive Treated With Rituximab, Chemotherapy and Tenofovir Alafenamide Rituximab, Chemotherapy, Tenofovir alafenamide - Large-B-cell Diffuse Lymphoma, Chronic Lymphoid Leukemia | Phase 2 | Terminated | Gruppo Italiano Malattie EMatologiche dell'Adulto | 5 | 2020-07-07 | 2025-02-27 |
| Preemptive Therapy for High Risk Chronic Lymphoid Leukemia Stage A Venetoclax - Chronic Lymphoid Leukemia | Phase 2 | Active not recruiting | French Innovative Leukemia Organisation | 82 | 2019-05-22 | 2025-11-26 |
| Allogeneic Hematopoietic Cell Transplantation From HLA-matched Donor After Flu-Mel-PTCy Versus Flu-Mel-ATG Reduced-intensity Conditioning Thymoglobulin, Melphalan, Fludarabine - Acute Myeloid Leukemia in Remission, Myelodysplastic Syndromes | Phase 2 | Recruiting | University of Liege | 114 | 2019-02-04 | 2022-10-12 |
| Sequential Regimen of Bendamustin-Debulking Followed by Obinutuzumab, Acalabrutinib and Venetoclax in Patients With Relapsed/Refractory CLL Bendamustine, Obinutuzumab, Acalabrutinib - Chronic Lymphoid Leukemia | Phase 2 | Completed | German CLL Study Group | 46 | 2019-01-14 | 2024-12-30 |
| The Effect of 25-OH-Vitamin-D3 Substitution in Patients With Malignant and Immune-hematologic Diseases Cholecalciferol, oleum neutralicum - Chronic Lymphoid Leukemia | Phase 3 | Terminated | Semmelweis University | 31 | 2012-01-01 | 2020-07-16 |
| Safety Study of ABT-263 in Combination With Rituximab in Lymphoid Cancers rituximab, ABT-263 - CD20-Positive Lymphoid Malignancies, Chronic Lymphoid Leukemia | Phase 1 | Completed | AbbVie | 29 | 2009-07-21 | 2025-02-20 |
| A Study of ABT-263 in Subjects With Relapsed or Refractory Lymphoid Malignancies ABT-263 - Chronic Lymphoid Leukemia, Lymphoid Malignancies | Phase 1 / Phase 2 | Completed | AbbVie (prior sponsor, Abbott) | 81 | 2006-11-01 | 2021-08-02 |
Leukemia, B-Cell (12) · Lymphoma, Non-Hodgkin (3) · Hematologic Neoplasms (2) · Graft vs Host Disease (1) · Hodgkin Disease (1) · Lymphoma, B-Cell, Marginal Zone (1) · Lymphoma, Follicular (1) · Lymphoma, Large B-Cell, Diffuse (1) · Lymphoma, Mantle-Cell (1) · Lymphoma, T-Cell, Cutaneous (1) · Lymphoma, T-Cell, Peripheral (1) · Multiple Myeloma (1) · Mycosis Fungoides (1) · Myelodysplastic Syndromes (1) · Myeloproliferative Disorders (1)
Hematologic Diseases (12) · Hemic and Lymphatic Diseases (12) · Immune System Diseases (12) · Immunoproliferative Disorders (12) · Leukemia (12) · Leukemia, Lymphoid (12) · Lymphatic Diseases (12) · Lymphoproliferative Disorders (12) · Neoplasms (12) · Neoplasms by Histologic Type (12) · Lymphoma (4) · Lymphoma, B-Cell (2) · Neoplasms by Site (2) · Blood Protein Disorders (1) · Bone Marrow Diseases (1)
venetoclax (4) · obinutuzumab (3) · Bendamustine Hydrochloride (2) · Rituximab (2) · acalabrutinib (2) · navitoclax (2) · Cholecalciferol (1) · Cyclophosphamide (1) · Drug Therapy (1) · Melphalan (1) · fludarabine (1) · ibrutinib (1) · tenofovir alafenamide (1) · thymoglobulin (1) · zanubrutinib (1)
German CLL Study Group (4) · AbbVie (1) · AbbVie (prior sponsor, Abbott) (1) · French Innovative Leukemia Organisation (1) · Gruppo Italiano Malattie EMatologiche dell'Adulto (1) · Private Hospital of Confluent, France (1) · Semmelweis University (1) · University Hospital, Toulouse (1) · University of Liege (1)
Germany (4) · France (3) · Austria (2) · Belgium (2) · Italy (2) · United States (2) · Australia (1) · Canada (1) · Denmark (1) · Finland (1) · Hungary (1) · Ireland (1) · Israel (1) · Netherlands (1) · Norway (1)
Paula Cramer, Dr. med. (2) · Alessandra Micozzi (1) · Barbara Eichhorst, Prof. (1) · Giuseppe Gentile (1) · Istvan Takacs, MD, PhD (1) · Mack Mabry, MD (1) · Othman Al-Sawaf, Dr. med. (1)
PMID 33236943, PMID 33559286, PMID 35594173, PMID 35988545, PMID 38620072, PMID 39883943, PMID 40906922, PMID 41358601
2017 (1), 2018 (1), 2019 (1), 2023 (1)